Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial - 18/02/21

Doi : 10.1016/j.ahj.2020.12.008

Ashish Sarraju, MD ^a, JingWei Li, PhD ^b, Christopher P. Cannon, MD ^c, Tara I. Chang, MD ^d, Rajiv Agarwal, MD ^e, George Bakris, MD ^f, David M. Charytan, MD ^g, Dick de Zeeuw, MD, PhD ^h, Tom Greene, PhD ⁱ, Hiddo J.L. Heerspink, PharmD, PhD ^b,^h, Adeera Levin, MD ^j, Bruce Neal, MB ChB, PhD ^b,^k, Carol Pollock, MBBS, PhD ^l, David C. Wheeler, MD ^b,^m, Yshai Yavin, MB ChB ⁿ, Hong Zhang, MD, PhD ^o, Bernard Zinman, MD ^p, Vlado Perkovic, MBBS, PhD ^b,^q, Meg Jardine, MBBS, PhD ^b, Kenneth W. Mahaffey, MD ^a,^⁎
^a Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA
^b The George Institute for Global Health, UNSW Sydney, New South Wales, Australia
^c Cardiovascular Division, Brigham & Women's Hospital and Baim Institute for Clinical Research, Boston, MA
^d Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
^e Indiana University School of Medicine and VA Medical Center, Indianapolis, Indiana
^f Department of Medicine, University of Chicago Medicine, Chicago, IL
^g Nephrology Division, NYU School of Medicine and NYU Langone Medical Center, New York, NY
^h Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
ⁱ Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, UT
^j Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada
^k Imperial College London, London, UK
^l Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia
^m Department of Renal Medicine, UCL Medical School, London, UK
ⁿ Janssen Research & Development, LLC, Raritan, NJ
^o Renal Division of Peking University First Hospital, Beijing, China
^p Lunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
^q The Royal North Shore Hospital, Sydney, Australia.

^⁎Reprint requests: Kenneth W. Mahaffey, MD, Stanford Center for Clinical Research, 300 Pasteur Drive, Stanford, CA 94305.Stanford Center for Clinical Research300 Pasteur DriveStanfordCA94305

Abstract

We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P < .001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.

Il testo completo di questo articolo è disponibile in PDF.

Mappa

Materials and methods

Results

Funding

Discussion

Clinical trial registration: URL: clinicaltrials.gov. Unique identifier: NCT02065791.

Esportazione

Vol 233

P. 141-148 - Marzo 2021 Ritorno al numero

Articolo precedente

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
Husam M. Salah, Subhi J. Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, J Paul Mounsey, Stephen J. Greene, Darren K. McGuire, Renato D. Lopes, Marat Fudim

| Articolo seguente

The paradox of implantable cardioverter-defibrillator: When guidelines may play against care improvement
Marcello Disertori, Michela Masè, Marta Rigoni, Flavia Ravelli, Giandomenico Nollo

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

connettersi o creare un account

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial - 18/02/21

Abstract

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL